Adaptive Biotechnologies (ADPT) Cash from Operations (2018 - 2026)

Adaptive Biotechnologies has reported Cash from Operations for 9 years, with the latest figure at 9537000.0 in Q1 2026.

• Quarterly Cash from Operations rose 66.52% year-over-year to 9537000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 27039000.0 (up 68.32% YoY) and the FY2025 annual result came in at 45986000.0, up 51.7% from the prior year.
• Cash from Operations declined to 9537000.0 in Q1 2026 per ADPT's latest filing, from 2055000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 2055000.0 in Q4 2025 and troughed at 64453000.0 in Q1 2022.
• A 5-year average of 28882588.24 and a median of 27065000.0 in 2024 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations fell 26.47% in 2022, then jumped 116.45% in 2025.
• Over 5 years, Cash from Operations stood at 30019000.0 in 2022, then gained by 10.28% to 26932000.0 in 2023, then surged by 53.62% to 12491000.0 in 2024, then surged by 116.45% to 2055000.0 in 2025, then tumbled by 564.09% to 9537000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 9537000.0, 2055000.0, and 7127000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.